press releases

home > press releases
Dec 15 Development of ADX10059 Ended for Long-term Use
Dec 14 Addex Ends Migraine Prevention Study
Dec 2 Addex Extends Parkinson’s Disease Collaboration with Merck & Co., Inc.
Nov 24 Addex ADX48621 Positive Primate Parkinson’s Data
Nov 16 Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial
Nov 3 Addex Presents ADX10059 PD-LID Data at GPCR Drug Discovery Conference
Sep 28 Addex completes enrollment of first mid-stage clinical GERD trial
Sep 17 Laurent Massuyeau, Head of Business Development, Resigns
Sep 14 Addex’ ADX10059 has potential for Parkinson’s disease levodopa induced dyskinesia (PD-LID)
Jul 28 Addex Pharmaceuticals Reports First Half 2009 Financial Results
Jul 23 Addex First Half 2009 Financial Results Tuesday, July 28
Jul 16 Addex R&D Day Highlights Broadened Therapeutic Potential of Allosteric Modulation Platform to Include Cytokine Receptors as well as GPCRs
Jul 10 Addex Achieves Second Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.
Jul 3 Addex to Host R&D Day on July 16
Jun 24 Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator
May 27 Glutamate Receptor “mGluR5” Implicated in GERD
Apr 29 Addex Presents Data on ADX10059 at the AAN
Apr 17 Addex Shareholders Approve All Board Proposals at 2009 AGM
Feb 24 Addex Pharmaceuticals 2008 Financial Results
Feb 17 Addex 2008 Full Year Financial Results Next Tuesday
Jan 28 Addex Successfully Completes ADX48621 Phase I Program